Treatment of Acquired Sideroblastic Anemias.

Abhishek A Mangaonkar, Mrinal M Patnaik

Journal: Hematology/oncology clinics of North America 2021;34(2):401-420

PMID: 32089219

Full Text on Elsevier Science View on PubMed

Abstract

Sideroblastic anemias are a heterogeneous group of disorders unified by the presence of abnormal erythroid precursors with perinuclear mitochondrial iron deposition in the bone marrow. Based on etiology, they are classified into clonal and nonclonal. Clonal sideroblastic anemias refer to myeloid neoplasms with ring sideroblasts (RS) and frequently have somatic perturbations in the SF3B1 gene. Anemia is a major cause of morbidity in patients, and restoration of effective erythropoiesis is a major treatment goal. Morbidity includes transfusion and disease-related complications. This article focuses on treatment of acquired sideroblastic anemias and highlights areas of future investigation.

Address: Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: [email protected].

DOI: 10.1016/j.hoc.2019.11.002

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-103

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-YWHAE-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Anemia, Sideroblastic, Biomarkers, Clonal Evolution, Combined Modality Therapy, Disease Management, Disease Progression, Disease Susceptibility, Erythroid Cells, Erythropoiesis, Hematinics, Humans, Hyperplasia, Immunologic Factors, Mutation, Myelodysplastic Syndromes, Treatment Outcome